0.92
-0.0299(-3.15%)
Currency In USD
Address
1300 South El Camino Real
San Mateo, CA 94402
United States of America
Phone
650 781 5200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
58
First IPO Date
October 09, 2020
| Name | Title | Pay | Year Born |
| Dr. Norbert W. Bischofberger Ph.D. | President, Chief Executive Officer & Director | 912,200 | 1956 |
| Mr. David M. Tanen J.D. | Secretary & Director | 40,000 | 1971 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 40,000 | 1977 |
| Dr. Charles Lin Ph.D. | Chief Scientific Officer | 0 | 1985 |
| Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations | 0 | N/A |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development | 0 | 1965 |
| Mr. Wes Trotter Ph.D. | Senior Vice President of Drug Discovery & Pharmaceutical Development | 0 | N/A |
| Dr. Deborah A. Knobelman Ph.D. | Chief Operating Officer & Chief Financial Officer | 0 | 1974 |
| Ms. Allison Frisbee J.D. | Chief Administrative Officer | 0 | 1983 |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.